Establishing state and national metrics to track progress in preventing diabetes
In 2014, the American Medical Association (AMA) and CDC initiated a strategic collaboration to prevent type 2 diabetes, bridging the gap between public health and clinical practice. The goal of this collaboration is to increase physician screening for prediabetes and referral of at-risk patients to diabetes prevention programs.
A 10-year plan to reduce the prevalence of type 2 diabetes by addressing prediabetes was framed through five strategic pillars. The pillars include raising awareness of prediabetes, increasing coverage and support for DPPs, improving physician screening, testing, and referrals to recognized DPPs, increasing availability and access to DPPs, and improving enrollment and completion rates for the DPP program.
This session provides an overview of the development of the strategic pillars that have feasibility for measuring state and national trends in diabetes prevention using multiple data sources; describes the metrics, and reports on an operational tracking system that can be applied to evaluate progress toward diabetes prevention.
Learning Areas:Chronic disease management and prevention
Clinical medicine applied in public health
Conduct evaluation related to programs, research, and other areas of practice
Public health or related laws, regulations, standards, or guidelines
Identify national and state metrics that will be used to track long-term progress in reducing the prevalence of type 2 diabetes through applying five strategic pillars.
Keyword(s): Prevention, Diabetes
Qualified on the content I am responsible for because: I am a Senior Economist for the American Medical Association's 'Improving Health Outcomes' team. My research focuses on economic studies of costs associated with diseases impacting a large percentage of the US population, physician and patient behaviors impact on outcomes and cost of care, and development of evaluation protocols to asses the impact of the team's initiatives.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.